KRT19 and hepatocellular carcinoma: Our previous study showed that a TGFβ receptor 1 inhibitor LY2157299 would be useful for the treatment of K19+ HCC in vitro and in vivo, and that TGFβ receptor 1 expression is significantly correlated with K19 expression in human HCC surgical specimens 14.